"Welcome to Trinity Health IHA Medical Group, Hematology Oncology - Chelsea (formerly IHA Hematology Oncology at St. Joe's Chelsea). We are a group of highly-specialized physicians and clinicians trained to care for patients with blood disorders and cancer. Our mission is to provide comprehensive and cutting-edge treatment in a professional and compassionate environment. Our patients benefit from accurate diagnosis, innovative treatment options and highly-coordinated care. We continue to make valuable strides into improving patient care through cancer research and our physicians actively participate as investigators in Trinity Health Hospital’s cancer research program."

During the past decade, Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital conducted 152 clinical trials. In the 10-year time frame, 152 clinical trials started and 34 clinical trials were completed, i.e. on average, 22.4% percent of trials that started reached the finish line to date. In the past 5 years, 82 clinical trials started and 34 clinical trials were completed. i.e. 41.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 78 trials, followed by "Alliance for Clinical Trials in Oncology" with 29 trials sponsored, "SWOG Cancer Research Network" with 28 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 12 trials sponsored and "NRG Oncology" with 12 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 89 trials as a collaborator, "NRG Oncology" with 11 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital" are "Stage IV Lung Cancer AJCC v8" (15 trials), "Stage IVA Lung Cancer AJCC v8" (11 trials), "Stage IVB Lung Cancer AJCC v8" (11 trials), "Recurrent Lung Non-Small Cell Carcinoma" (8 trials) and "Stage IIIB Lung Cancer AJCC v8" (7 trials). Many other conditions were trialed in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital" in a lesser frequency.

Most popular intervention types in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital" are "Drug" (135 trials), "Other" (100 trials), "Biological" (65 trials), "Procedure" (48 trials) and "Radiation" (23 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (54 trials), "Questionnaire Administration" (40 trials), "Computed Tomography" (33 trials), "Biospecimen Collection" (32 trials) and "Laboratory Biomarker Analysis" (30 trials). Other intervention names were less common.

The vast majority of trials in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital" are 146 trials for "All" genders, 17 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital". undefined are not yet recruiting, 72 are recruiting, 70 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, 9 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, 2 "Phase 1" clinical trials were conducted, 87 "Phase 2" clinical trials and 91 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".